RxDoctor Payments Data

Rod Lewis, NP

Family · Dalton, GANPI 1043523897

Payments from drug & device makers

$4,445in general payments, 2019–2025

Across 243 payments — averaging $18.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$806
  • Lilly USA, LLC$517
  • Novo Nordisk$408
  • Pfizer$390
  • Takeda Pharmaceuticals U.S.A., Inc.$238
  • Otsuka America Pharmaceutical, Inc.$168
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$4,445100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,445 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$123,327
Medicare patients
365
Services billed
2,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban146$161,205
TrulicityDulaglutide68$94,669
JardianceEmpagliflozin57$66,810
OzempicSemaglutide58$66,244
FarxigaDapagliflozin Propanediol50$54,333
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$51,413
LinzessLinaclotide30$25,675
JanuviaSitagliptin Phosphate16$25,096
EntrestoSacubitril/Valsartan22$22,809
Breo ElliptaFluticasone/Vilanterol41$21,599
MyrbetriqMirabegron27$19,897
JanumetSitagliptin Phos/Metformin Hcl18$19,839
XareltoRivaroxaban19$19,541
VascepaIcosapent Ethyl19$14,810
PentasaMesalamine12$13,190

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$390$161,205146 claims
Lilly USA, LLCTrulicity$517$94,66968 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$79$85,073110 claims
AstraZenecaFarxiga, Symbicort, Brilinta$102$78,64098 claims
Boehringer IngelheimJardiance$101$66,81057 claims
Novo NordiskOzempic$408$66,24458 claims
MerckJanuvia, Janumet$65$44,93534 claims
AbbVieLinzess$806$25,67530 claims
Astellas Pharma US IncMyrbetriq$19$19,89727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.

Other family in Dalton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →